A
Asimov
Synthetic biology company building tools to design living systems
About Asimov
Asimov operates in the synthetic biology sector, providing an integrated suite of cells, genes, and software to power advanced genetic design. The company serves clients in the biopharmaceutical industry, including those involved in biologics, gene therapy, and programmable medicines. Asimov's core offerings include cloud-based software for designing, simulating, and optimizing genetic systems, as well as engineered GMP host cells for therapeutic applications. The business model revolves around providing these high-tech solutions to biopharma companies, enabling them to achieve high titers in protein therapeutics production and scalable viral vector production. Revenue is generated through the sale of software licenses, engineered cell lines, and associated services such as process development and stability studies. Asimov guarantees high titer cell lines for monoclonal antibodies, offering a '4 g/L or it's free' promise, which mitigates the risk for their clients. The company leverages its in-house synthetic biology, cell line development, and process development teams to ensure the highest quality and performance of their products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Boston, United States
- Employees
- 121
- Open positions
- None listed
- Dealroom signal
- 89.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Synthetic Biology, Spinout, Rumoured $1B, AI Drug Discovery, Techbio, CompBio
- Technology
- Artificial Intelligence, Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2023 | $175M | $700M | Horizons Ventures · KdT Ventures · Andreessen Horowitz · Fidelity Investments | ↗ |
| SERIES AOther financing | Dec 2019 | $25M | $100M | Horizons Ventures | ↗ |
Growth signals
Latest recorded traffic for Asimov is 42K monthly website visits, down 31.1% over the last three months. Asimov's team grew 16.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A7 investors entered at this stage
Horizons Ventures
CPP Investments
KdT Ventures
Andreessen Horowitz
Fidelity Investments
Casdin Capital
Pillar VC
Other known investors2 additional known investors
Boston University
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asimov on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asimov’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.